Larry Ereshefsky Pharmd, Fccp, Bcpp Email and Phone Number
Larry Ereshefsky Pharmd, Fccp, Bcpp work email
- Valid
Larry Ereshefsky Pharmd, Fccp, Bcpp personal email
• Chief Scientific Officer, Early Phase, @CenExel Research (APEX Innovative Sciences acquired)• Consultant supporting Pharma, clinical investigator, and accomplished CNS translational/clinical scientist, drug development strategies using neurocircuitry (fMRI/PET/QEEG/ERP), CSF biomarkers, PK/PD. • Chief Scientist Early Phase Development at Collaborative Neuroscience Network (CNSNetwork)• Chief Scientist Early Phase Development at Hassman Research Institute• Consultant Later Phase Development at Proscience Research LLC• Clinical development plan and regulatory support, including pre-IND, IND launch to First into Human studies, and end of Phase II• Supports due diligence, intellectual property, and legal expert witness/consultant review. Scope includes novel investigational drugs and small biotech companies for acquisition or venture capital support. Expert witness/legal consultant for pharmacotherapy, pharmacology/kinetics/tox, and dosage formulation patent/intellectual property claims• Clinical investigator and rating scales assessments; focus on improving signal detection, reducing placebo 'response', and enhancing patient adherence• Internationally recognized clinical psychiatric pharmacist and have supported commercialization and pharmacoeconomic analyses for health system of new medications• Currently chair the working group at International Society for CNS Clinical Trials Methodology for drug development of Behavioral and Psychiatric Symptoms in Dementia• Retired Professor of Pharmacy/Pharmacology/Psychiatry at University of Texas (Austin and Health Science Center, San Antonio). Retired VP Early Phase and Global Leader CNS from PAREXEL International• Previously Associate Director, Clinical Research, San Antonio State Hospital, co-Directed the Applied Psychopharmacology and Evaluation Laboratory, and Director of the Psychiatric Pharmacy Program at the University of Texas. • For more than 15 years served on the United States Pharmacopeia Committee for Psychiatry and served twice on the FDA Psychopharmacological Drugs Advisory Committee.
Follow The Molecule Llc
View- Employees:
- 1
-
Cso And Owner, Follow The Molecule LlcFollow The Molecule LlcMarina Del Rey, Ca, Us
-
Chief Scientific OfficerCenexel (Formerly Apex Innovative Sciences) Jun 2022 - PresentEarly phase clinical Research; biomarkers and translational strategies
-
Apex Innovative Sciences, Chief Scientific OfficerCenexel (Formerly Apex Innovative Sciences) Oct 2019 - Sep 2022Supporting/designing and implementing translational CNS early phase studies and providing consultative support to our clients. Working with an amazing staff at our two core facilities where we try to contribute towards making a difference in our patient's well being. Drug development strategies to partly de-risk entry into Phase II incorporating our in place harmonized technologies at two Early Phase Units: HRI and CNS. We have over the past 2 years, and currently, support numerous studies in the biomarker/target engagement space incorporating in a fit for purpose design: fMRI, MRS,. and/or QEEG, ERP, PSG, and/or CSF sampling etc.
-
Clinical Psychopharmacology ConsultantProscience Research Group May 2007 - PresentCulver City, California, Us -
Chief Scientific OfficerFollow The Molecule: Cns Consulting Llc May 2018 - PresentHave conducted 200+ early phase trials in CNS, medical, Asian bridging, and HNV populations including FiH SAD/MAD, DDI, BA/BE, 505b2, and POCs. Have expertise in designing and conducting studies incorporating experimental medicine strategies, as well as translational drug development tools supporting neurocircuitry/biomarker based (RDoC) strategies, i.e., continuous CSF sampling, QEEG, ERP, PSG, sMRI, fMRI, PET, and cognitive and behavioral paradigms.
-
Chief Scientific Officer, Hassman Research Institute And Cns ResearchFollow The Molecule: Cns Consulting Llc Mar 2017 - PresentHassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and advancing the company’s Early Phase Development Division focusing on diseases. He will report to Dr. Howard Hassman, CSO of HRI.“I am enthusiastic about Dr. Larry Ereshefsky joining HRI as chief scientific officer, Early Phase Development. He has an extensive record of innovative scientific contributions and will bring years of expertise and insight to the company,” said Dr. Hassman. “I believe Dr. Ereshefsky and the team at HRI have positioned the company for success and I welcome the opportunity to make a positive impact on the ongoing development of new therapeutic approach to help patients with Psychiatric and Neurologic Disorders, Pain, Addiction and countless other diseases.”
-
Cso And Owner, Follow The Molecule LlcFollow The Molecule: Cns Consulting Llc Jul 2016 - PresentAs CSO, he provides support for clinical program development ‘following the molecule” from early through late phase development. He has been a clinical investigator and a credentialed clinician since 1977. He is a global consultant for Pharma, technology companies, and clinical sites; has extensive experience working with the FDA/EMA. He also has forensic/legal experience. He has 177 publications. He was instrumental in the sale of CCT to PAREXEL and provides due diligence for Pharma and Capital Investment groups. Larry applies his years of experience as a clinician, scientist and investigator, supported by Federal/State/Foundation, CRO, and Pharma, to develop treatments and innovate clinical methodologies to make a difference in the lives of patients with Schizophrenia, Bipolar, Major Depressive, Anxiety and Sleep disorders, Alzheimer’s Disease, Parkinson’s Disease, ADHD, and Chronic Pain syndromes. He has a proven track record in designing and performing complex, integrated (umbrella) and adaptive Phase I-IIA studies. He also has extensive experience conducting studies using enriched population strategies. He has been a leader in the application of translational drug development tools including neurocircuitry/biomarker based (RDoC) strategies (i.e., continuous CSF sampling, QEEG, ERP, PSG, sMRI, fMRI, fcMRI, PET, and cognitive and behavioral paradigms) for many CNS disorders, including schizophrenia, depression and neurodegenerative disorders. He guides analyses exploring PK/PD modeling, including concentration/QTc, His expertise includes evaluation of toxicology and safety signals, especially in translating the preclinical and clinical study data into design strategies incorporating patient assessments/biomarkers, risk mitigation strategies, and in exploring exposure limits.
-
Vp Early Phase & Cns Global Therapeutic Area Leader, Early Phase (Retired)Parexel Jun 2013 - Jun 2016Durham, North Carolina, UsTotal of 13 years as an Executive and CSO and/or lead clinical scientist for Early Phase CNS, now retired. Responsibilities ranged from responsibilities for Scientific Affairs support of Business development, CRU activities ranging from PI-Sub-I, staff training, clinical consulting, design/implement/interpret specialized evaluations including fMRI, PET, QEEG, ERP, various customized assessment platforms supporting an RDoC strategy for drug development. Scientific, clinical, and business support was provided globally. Presented and consulted as an International thought leader, consultant for Pharma at the EMA and FDA . -
Vp, Principal Clinical Pharmacologist And Psychiatric Therapeutic ExpertParexel 2006 - Jun 2013Durham, North Carolina, Us
-
Vp, Chief Scientific OfficerParexel/Cct Aug 2003 - Jun 2008Facilitated the sale of CCT to PAREXEL, by providing value added scientific consulting to enhance the overall business model and competitiveness of our clinical trials unit
-
Chief Scientific Officer, Executive Vice PresidentCalifornia Clinical Trials 2003 - 2008
-
Professor Pharmacy, Psychiatry And Pharmacology (Retired)Ut Health Science Center At San Antonio 1977 - 2003San Antonio, Tx, Us26 years full time, retired. Ongoing teaching and consulting activities; member of UT College of Pharmacy Advisory Council -
Assoc Director, Research; Clin PharmacologistSan Antonio State Hospital 1977 - 2003
Larry Ereshefsky Pharmd, Fccp, Bcpp Skills
Larry Ereshefsky Pharmd, Fccp, Bcpp Education Details
-
University Of Southern CaliforniaPsychopharmacology -
UclaPsychobiology Major
Frequently Asked Questions about Larry Ereshefsky Pharmd, Fccp, Bcpp
What company does Larry Ereshefsky Pharmd, Fccp, Bcpp work for?
Larry Ereshefsky Pharmd, Fccp, Bcpp works for Follow The Molecule Llc
What is Larry Ereshefsky Pharmd, Fccp, Bcpp's role at the current company?
Larry Ereshefsky Pharmd, Fccp, Bcpp's current role is CSO and Owner, Follow the Molecule LLC.
What is Larry Ereshefsky Pharmd, Fccp, Bcpp's email address?
Larry Ereshefsky Pharmd, Fccp, Bcpp's email address is bc****@****sci.com
What schools did Larry Ereshefsky Pharmd, Fccp, Bcpp attend?
Larry Ereshefsky Pharmd, Fccp, Bcpp attended University Of Southern California, Ucla.
What skills is Larry Ereshefsky Pharmd, Fccp, Bcpp known for?
Larry Ereshefsky Pharmd, Fccp, Bcpp has skills like Clinical Development, Migraine, Therapeutic Area, Clinical Trials, Neuroscience, Clinical Research, Pharmacology, Genetics, Technology Transfer, Smoking Cessation, Oncology, Medicine.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial